ABNCoV2

{{short description|Vaccine candidate against COVID-19}}

{{Use dmy dates|date=December 2021}}

{{Infobox drug

| Verifiedfields =

| verifiedrevid =

| drug_name =

| INN =

| type = vaccine

| image =

| alt =

| caption =

| target = SARS-CoV-2

| vaccine_type = vlp

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_EU =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status =

| routes_of_administration = Intramuscular

| CAS_number = 2698316-97-9

| CAS_number_Ref = {{cite web|url=https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-en-covid-19-related-vaccines-and-therapeutics.pdf|title=Patent Landscape Report COVID-19-related vaccines and therapeutics}}

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms =

}}

{{COVID-19 pandemic sidebar}}

ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.{{cite news|title=Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial |url=https://www.bavarian-nordic.com/investor/news/news.aspx?news=6178 |access-date=13 April 2021 |website=Bavarian Nordic |date=8 March 2021}}{{ClinicalTrialsGov|NCT04839146|Safety and Tolerability of ABNCoV2 (COUGH-1)}}{{cite news | title=Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine |url=https://view.news.eu.nasdaq.com/view?id=b2990620f9697f3fecb6a816bdbc726c9&lang=en |access-date=24 August 2021 |publisher=Bavarian Nordic |date=23 August 2021}}{{ClinicalTrialsGov|NCT05077267|ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects}}

On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.{{Cite web | vauthors = Svansø VL |date=2021-08-09 |title=Foreløbige resultater: Dansk vaccine virker i første forsøg med mennesker – og den virker godt |url=https://www.berlingske.dk/content/item/1582503 |access-date=2023-01-25 |website=Berlingske.dk |language=da}}